reduce basal insulin when starting glp-1 receptor agonist GLP1-RA and SGLT2-i: Implementation and Deescalation Strategies | Cardiovascular Drugs and Therapy Trends in the Development of

The study also indicated that GLP-1 RA treatment was associated with a moderately increased risk of gallstones (RR: 1.27, 95% CI 1.101.47), cholecystitis (RR: 1.36, 95% CI 1.141.62), and overall gallbladder disease risk (RR: 1.55, 95% CI 1.082.22) compared to placebo

Tirzepatide acts on GIP and GLP-1 receptors to help control insulin release and appetite

Learn More Zepbound vials Available via LillyDirect Medication cost billed by LillyDirect A once-weekly injectable GLP-1/GIP dual agonist indicated for the treatment of overweight and obesity

Unlock the secrets to effective weight management with "The GLP-1 Meal Plan" by Certified Nutritionist Maggie Brown